170 related articles for article (PubMed ID: 17918261)
1. Haptoglobin and posttranslational glycan-modified derivatives as serum biomarkers for the diagnosis of nonsmall cell lung cancer.
Hoagland LF; Campa MJ; Gottlin EB; Herndon JE; Patz EF
Cancer; 2007 Nov; 110(10):2260-8. PubMed ID: 17918261
[TBL] [Abstract][Full Text] [Related]
2. A multiparametric serum kallikrein panel for diagnosis of non-small cell lung carcinoma.
Planque C; Li L; Zheng Y; Soosaipillai A; Reckamp K; Chia D; Diamandis EP; Goodglick L
Clin Cancer Res; 2008 Mar; 14(5):1355-62. PubMed ID: 18316555
[TBL] [Abstract][Full Text] [Related]
3. Diagnosis value of serum B7-H3 expression in non-small cell lung cancer.
Zhang G; Xu Y; Lu X; Huang H; Zhou Y; Lu B; Zhang X
Lung Cancer; 2009 Nov; 66(2):245-9. PubMed ID: 19269710
[TBL] [Abstract][Full Text] [Related]
4. Serum levels of apoptosis biomarkers, survivin and TNF-alpha in nonsmall cell lung cancer.
Derin D; Soydinç HO; Guney N; Tas F; Camlica H; Duranyildiz D; Yasasever V; Topuz E
Lung Cancer; 2008 Feb; 59(2):240-5. PubMed ID: 17875341
[TBL] [Abstract][Full Text] [Related]
5. Study of serum haptoglobin and its glycoforms in the diagnosis of hepatocellular carcinoma: a glycoproteomic approach.
Ang IL; Poon TC; Lai PB; Chan AT; Ngai SM; Hui AY; Johnson PJ; Sung JJ
J Proteome Res; 2006 Oct; 5(10):2691-700. PubMed ID: 17022640
[TBL] [Abstract][Full Text] [Related]
6. Clinical utility of serum amyloid A and macrophage migration inhibitory factor as serum biomarkers for the detection of nonsmall cell lung carcinoma.
Khan N; Cromer CJ; Campa M; Patz EF
Cancer; 2004 Jul; 101(2):379-84. PubMed ID: 15241837
[TBL] [Abstract][Full Text] [Related]
7. Altered desialylated plasma N-glycan profile in patients with non-small cell lung carcinoma.
Bartling B; Vanhooren V; Dewaele S; Libert C; Hofmann HS; Haerting J; Nuding S; Silber RE; Simm A; Chen CC
Cancer Biomark; 2011-2012; 10(3-4):145-54. PubMed ID: 22674300
[TBL] [Abstract][Full Text] [Related]
8. Haptoglobin alpha-subunit and hepatocyte growth factor can potentially serve as serum tumor biomarkers in small cell lung cancer.
Bharti A; Ma PC; Maulik G; Singh R; Khan E; Skarin AT; Salgia R
Anticancer Res; 2004; 24(2C):1031-8. PubMed ID: 15154618
[TBL] [Abstract][Full Text] [Related]
9. Relationship between N-linked oligosaccharide chains of human serum immunoglobulin G and serum tumor markers with non-small cell lung cancer progression.
Kanoh Y; Ohara T; Mashiko T; Abe T; Masuda N; Akahoshi T
Anticancer Res; 2006; 26(6B):4293-7. PubMed ID: 17201147
[TBL] [Abstract][Full Text] [Related]
10. Clinical usefulness of alpha-crystallin antibodies in non-small cell lung cancer patients.
Cherneva R; Petrov D; Georgiev O; Trifonova N
Interact Cardiovasc Thorac Surg; 2010 Jan; 10(1):14-7. PubMed ID: 19797476
[TBL] [Abstract][Full Text] [Related]
11. Elevation of serum l-lactate dehydrogenase B correlated with the clinical stage of lung cancer.
Chen Y; Zhang H; Xu A; Li N; Liu J; Liu C; Lv D; Wu S; Huang L; Yang S; He D; Xiao X
Lung Cancer; 2006 Oct; 54(1):95-102. PubMed ID: 16890323
[TBL] [Abstract][Full Text] [Related]
12. Differentially expressed serum haptoglobin alpha chain isoforms with potential application for diagnosis of head and neck cancer.
Chen CB; Su YC; Huang TT; Ho HC; Chang YT; Tung YT; Lee WC
Clin Chim Acta; 2008 Dec; 398(1-2):48-52. PubMed ID: 18727923
[TBL] [Abstract][Full Text] [Related]
13. Serum endostatin levels in patients with lung carcinoma.
Swidzińska E; Ossolińska M; Naumnik W; Trojan S; Chyczewska E
Rocz Akad Med Bialymst; 2005; 50():197-200. PubMed ID: 16358965
[TBL] [Abstract][Full Text] [Related]
14. Subunit-specific mass spectrometry method identifies haptoglobin subunit alpha as a diagnostic marker in non-small cell lung cancer.
Park J; Yang JS; Jung G; Woo HI; Park HD; Kim JW; Huh W; Ko JW; Kim H; Cho JY; Lee SY
J Proteomics; 2013 Dec; 94():302-10. PubMed ID: 24120528
[TBL] [Abstract][Full Text] [Related]
15. Value of tumour and inflammatory markers in lung cancer.
Oremek GM; Sauer-Eppel H; Bruzdziak TH
Anticancer Res; 2007; 27(4A):1911-5. PubMed ID: 17649794
[TBL] [Abstract][Full Text] [Related]
16. The Haptoglobin β chain as a supportive biomarker for human lung cancers.
Kang SM; Sung HJ; Ahn JM; Park JY; Lee SY; Park CS; Cho JY
Mol Biosyst; 2011 Apr; 7(4):1167-75. PubMed ID: 21253648
[TBL] [Abstract][Full Text] [Related]
17. Centromere protein H is a novel prognostic marker for human nonsmall cell lung cancer progression and overall patient survival.
Liao WT; Wang X; Xu LH; Kong QL; Yu CP; Li MZ; Shi L; Zeng MS; Song LB
Cancer; 2009 Apr; 115(7):1507-17. PubMed ID: 19170237
[TBL] [Abstract][Full Text] [Related]
18. Circulating plasma DNA as diagnostic biomarker in non-small cell lung cancer.
Paci M; Maramotti S; Bellesia E; Formisano D; Albertazzi L; Ricchetti T; Ferrari G; Annessi V; Lasagni D; Carbonelli C; De Franco S; Brini M; Sgarbi G; Lodi R
Lung Cancer; 2009 Apr; 64(1):92-7. PubMed ID: 18804892
[TBL] [Abstract][Full Text] [Related]
19. Quantification of free circulating DNA as a diagnostic marker in lung cancer.
Sozzi G; Conte D; Leon M; Ciricione R; Roz L; Ratcliffe C; Roz E; Cirenei N; Bellomi M; Pelosi G; Pierotti MA; Pastorino U
J Clin Oncol; 2003 Nov; 21(21):3902-8. PubMed ID: 14507943
[TBL] [Abstract][Full Text] [Related]
20. Glycoproteomics analysis to identify a glycoform on haptoglobin associated with lung cancer.
Tsai HY; Boonyapranai K; Sriyam S; Yu CJ; Wu SW; Khoo KH; Phutrakul S; Chen ST
Proteomics; 2011 Jun; 11(11):2162-70. PubMed ID: 21538882
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
